Peter de Haan
Founder at Amarna Therapeutics BV
Peter de Haan active positions
| Companies | Position | Start | End |
|---|---|---|---|
Barranco Resources NL
 Barranco Resources NL Wholesale DistributorsDistribution Services Barranco Resources NL provides mineral exploration services. The firm is also engaged in discovery, evaluation, and development of mineral resources. The company is headquartered in City Beach, Australia. | Director/Board Member | - | - |
Amarna Therapeutics BV
 Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Chief Tech/Sci/R&D Officer | 01/01/2009 | - |
| Founder | 01/01/2008 | - |
Career history of Peter de Haan
Statistics
International
| Australia | 2 |
| Netherlands | 2 |
Operational
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectoral
| Distribution Services | 2 |
| Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Barranco Resources NL
Barranco Resources NL Wholesale DistributorsDistribution Services Barranco Resources NL provides mineral exploration services. The firm is also engaged in discovery, evaluation, and development of mineral resources. The company is headquartered in City Beach, Australia. | Distribution Services |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Health Services |
- Stock Market
- Insiders
- Peter de Haan
- Experience
